Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
about
Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivationNew steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death.Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cellsSilencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.Altered radiation responses of breast cancer cells resistant to hormonal therapyMore on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response.Multiple gene aberrations and breast cancer: lessons from super-responders.Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancererbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines.MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathwaysFemara and the future: tailoring treatment and combination therapies with Femara.Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinaseKnockdown of the small conductance Ca(2+) -activated K(+) channels is potently cytotoxic in breast cancer cell lines.Evaluation of the current knowledge limitations in breast cancer research: a gap analysisMechanisms of endocrine resistance in breast cancer.The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cellsImpact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells.IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.
P2860
Q21195230-A44DF650-34C9-49A3-811A-1D58BCB18078Q33354763-A7D99DBE-FF7A-4A32-A0F0-BA7EC6AAC3D8Q33917551-32AF8B10-8648-4601-9271-9EEDB1414B1FQ34367908-9BC44C5F-7D47-4918-8221-037A7EC0B493Q34923304-69EDA56B-7A01-468F-929D-430B762D6E14Q35176411-F71721B0-BBCA-4532-ADEB-0D05D2BBCCB7Q35558957-FD66D68A-872A-43A1-A5FF-2D667502C46AQ35645466-8523F5FE-686E-4D1B-84BF-8C75FAA6AA4DQ35677725-A6E6E203-E87A-494F-B2C3-756A31A7869FQ35683561-B3FCD2CB-7D3A-4A8C-AE19-827268D03CBFQ35930474-87095918-3206-47EC-8023-EA894C00CE8CQ36026429-4AAC303C-5E75-4FEA-8C1F-734E1061BFB4Q36135818-339056A0-30E8-41EB-AE44-0892377A53B1Q36533102-4EC82643-E2DA-4F9F-962D-B99080DF99F2Q36678664-7A70E2B8-1A09-4C64-8D26-22A7246A8718Q36851417-6ACC1470-92A0-4588-AC86-4876BCACF262Q36955067-14F6C9CA-3590-497A-9470-C89F1686A827Q37131348-16B74462-0D59-4A75-9980-D49663F021E8Q37690245-86DA68B8-A51D-4CC2-A7A6-8A63C1D1A7C9Q38349268-FD6CF8DE-67CD-4E59-A0DC-273A43313329Q39654146-94CB1437-8644-46C0-A32C-9ED5DCFD4A75Q39720714-D633AEB4-7856-4B60-BD7E-44F8C51555A1Q54610139-035DAA33-D023-42FC-8478-3A724E7D75A4
P2860
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Growth factor signalling and r ...... e resistance in breast cancer.
@ast
Growth factor signalling and r ...... e resistance in breast cancer.
@en
type
label
Growth factor signalling and r ...... e resistance in breast cancer.
@ast
Growth factor signalling and r ...... e resistance in breast cancer.
@en
prefLabel
Growth factor signalling and r ...... e resistance in breast cancer.
@ast
Growth factor signalling and r ...... e resistance in breast cancer.
@en
P2093
P356
P1476
Growth factor signalling and r ...... ne resistance in breast cancer
@en
P2093
Hutcheson IR
Knowlden JM
Nicholson RI
P304
P356
10.1677/ERC.1.00991
P478
12 Suppl 1
P577
2005-07-01T00:00:00Z